It turns out that in comparison with the placebo control group, his fasting blood glucose, triglyceride, low-density lipoprotein (LDL-C) and C-reactive protein (CRP) levels were reduced, and the ADP-induced platelet activation and p-selectin levels were inhibited, thereby decreasing cardiovascular risk factors and reducing thrombogenicity in a MetS population (ClinicalTrials.gov Identifier: ACTRN12615000293561) (Aboonabi et al., 2020). This evidence concerns the gene CRP and metabolic syndrome.